Progress versus Pseudoprogress beim Lungenkarzinom unter Immuntherapie

Progress versus Pseudoprogress beim Lungenkarzinom unter Immuntherapie

Bibliographic Details
Main Author:	Schiwitza, Annett Jenny
Other Authors:	Andreas, Stefan Prof. Dr.
Format:	Doctoral Thesis
Language:	deu
Published:	2020
Subjects:	610 Immuntherapy Checkpoint-Inhibitoren Lungenkarzinom PD-1/PD-L1 Inhibition prädiktive Marker Immunotherapy Checkpoint-Inhibition lung cancer PD-1/PD-L1 inhibition predictive marker Onkologie (PPN619875895)
Online Access:	http://hdl.handle.net/21.11130/00-1735-0000-0005-146D-B http://nbn-resolving.de/urn:nbn:de:gbv:7-21.11130/00-1735-0000-0005-146D-B-7

Similar Items

Addition of Radiotherapy to Immunotherapy: Effects on Outcome of Different Subgroups Using a Propensity Score Matching
by: Maike Trommer, et al.
Published: (2020-08-01)

Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
by: Zuzana Macek Jilkova, et al.
Published: (2019-10-01)

Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma
by: Dirk Schadendorf, et al.
Published: (2017-10-01)

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
by: Kristina Buder-Bakhaya, et al.
Published: (2018-06-01)

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
by: Florus C. de Jong, et al.
Published: (2021-03-01)

Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma
by: Christiane Kümpers, et al.
Published: (2019-03-01)

Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate
by: Hanno M. Witte, et al.
Published: (2020-04-01)

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
by: Alfredo Addeo, et al.
Published: (2019-04-01)

PD-L1 Expression in Mastocytosis
by: Margaret Williams, et al.
Published: (2019-05-01)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
by: Jing W, et al.
Published: (2016-01-01)

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
by: Solène-Florence Kammerer-Jacquet, et al.
Published: (2019-04-01)

Expression patterns of immune checkpoints in acute myeloid leukemia
by: Cunte Chen, et al.
Published: (2020-04-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
by: Sebastian Marwitz, et al.
Published: (2017-05-01)

Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer
by: Joe Yeong, et al.
Published: (2019-02-01)

Cancer immunotherapies targeting the PD-1 signaling pathway
by: Yoshiko Iwai, et al.
Published: (2017-04-01)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
by: Federica Costa, et al.
Published: (2018-09-01)

Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
by: Florian Wirsdörfer, et al.
Published: (2018-12-01)

Research Progress of PD-1/PD-L1/2 Pathway in Multiple Myeloma
by: MA Yinjuan, et al.
Published: (2021-06-01)

PREDICTIVE RESPONSE MARKERS FOR IMMUNE RESPONSE BLOCKS
by: G. A. Janus, et al.
Published: (2020-09-01)

Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of <i>KRAS</i>-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8<sup>+</sup> T Cells
by: Iosune Baraibar, et al.
Published: (2020-10-01)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
by: Melanie Janning, et al.
Published: (2019-06-01)

Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III–IV Melanoma: A Systematic Review and Meta-Analysis
by: Ye Liu, et al.
Published: (2021-06-01)

Checkpoint inhibitors in hematological malignancies
by: Chi Young Ok, et al.
Published: (2017-05-01)

Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
by: Jingjing Fan, et al.
Published: (2020-10-01)

Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency
by: Anaïs Perrichet, et al.
Published: (2020-11-01)

PD-L1 immune suppression in cancer: Tumor cells or host cells?
by: Jan Willem Kleinovink, et al.
Published: (2017-07-01)

Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
by: Grace Wakabayashi, et al.
Published: (2019-12-01)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
by: Jan Willem Kleinovink, et al.
Published: (2017-04-01)

Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy
by: Maxim Shevtsov, et al.
Published: (2019-03-01)

SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art
by: Lisa H. Butterfield, et al.
Published: (2018-12-01)

Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy
by: Daniele Lecis, et al.
Published: (2019-05-01)

Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
by: Zhiyu HUANG, et al.
Published: (2015-11-01)

Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
by: Xinyu Yan, et al.
Published: (2018-09-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
by: Jing Huang, et al.
Published: (2017-05-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
by: YU Lin, et al.
Published: (2021-08-01)

Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy
by: Sven H. H. Loosen, et al.
Published: (2021-03-01)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
by: Juwon Lee, et al.
Published: (2021-07-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
by: Edyta Zyla, et al.
Published: (2021-08-01)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
by: Alberto Bongiovanni, et al.
Published: (2021-05-01)

Cannot write session to /tmp/vufind_sessions/sess_5nc2s0u4nl1bimgs7noucdavkf